Cargando…

Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson’s Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). Despite the extensive research on this disease, on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peña-Díaz, Samuel, García-Pardo, Javier, Ventura, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059018/ https://www.ncbi.nlm.nih.gov/pubmed/36986700 http://dx.doi.org/10.3390/pharmaceutics15030839

Ejemplares similares

Small molecules to prevent the neurodegeneration caused by α-synuclein aggregation
por: Peña-Díaz, Samuel, et al.
Publicado: (2020)

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease
por: Vittorio, Serena, et al.
Publicado: (2020)

One ring is sufficient to inhibit α-synuclein aggregation
por: Peña-Díaz, Samuel, et al.
Publicado: (2021)

Inducing α-synuclein compaction: a new strategy for inhibiting α-synuclein aggregation?
por: Pinheiro, Francisca, et al.
Publicado: (2019)

Small molecules to target tau amyloid aggregation
por: Manglano-Artuñedo, Zoe, et al.
Publicado: (2023)

Ligand-Based Discovery of a Small Molecule as Inhibitor of α-Synuclein Amyloid Formation
por: De Luca, Laura, et al.
Publicado: (2022)

ZPD-2, a Small Compound That Inhibits α-Synuclein Amyloid Aggregation and Its Seeded Polymerization
por: Peña-Díaz, Samuel, et al.
Publicado: (2019)

The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple α-synuclein strains
por: Peña-Díaz, Samuel, et al.
Publicado: (2022)

Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of α-Synuclein Amyloids in Parkinson's Disease
por: Paul, Ashim, et al.
Publicado: (2019)

Inhibition of α-Synuclein Aggregation and Mature Fibril Disassembling With a Minimalistic Compound, ZPDm
por: Peña-Díaz, Samuel, et al.
Publicado: (2020)

High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors
por: Pujols, Jordi, et al.
Publicado: (2017)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
por: Emin, Derya, et al.
Publicado: (2022)

Models of α-synuclein aggregation in Parkinson’s disease
por: Giráldez-Pérez, Rosa María, et al.
Publicado: (2014)

Optimization of a small molecule inhibitor of secondary nucleation in α-synuclein aggregation
por: Staats, Roxine, et al.
Publicado: (2023)

A small molecule 20C from Gastrodia elata inhibits α-synuclein aggregation and prevents progression of Parkinson’s disease
por: Peng, Ye, et al.
Publicado: (2023)

Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of α-Synuclein Aggregates
por: Chia, Sean, et al.
Publicado: (2022)

Small Molecule Fisetin Modulates Alpha–Synuclein Aggregation
por: Rosado-Ramos, Rita, et al.
Publicado: (2021)

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
por: Tatenhorst, Lars, et al.
Publicado: (2016)

Uncovering the Role of Natural and Synthetic Small Molecules in Counteracting the Burden of α-Synuclein Aggregates and Related Toxicity in Different Models of Parkinson’s Disease
por: Mohammed, Salihu, et al.
Publicado: (2023)

α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity
por: Santos, Jaime, et al.
Publicado: (2021)

Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease
por: Tóth, Gergely, et al.
Publicado: (2014)

Anionic Nanoplastic Contaminants Promote Parkinson’s Disease-Associated α-Synuclein Aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter
por: Staats, Roxine, et al.
Publicado: (2020)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

The Aggregation of Huntingtin and α-Synuclein
por: Chánez-Cárdenas, María Elena, et al.
Publicado: (2012)

Monitoring α-synuclein aggregation
por: Estaun-Panzano, Juan, et al.
Publicado: (2023)

Correction: Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease
Publicado: (2014)

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
por: Javed, Hayate, et al.
Publicado: (2019)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Dynamics of a model for the degradation mechanism of aggregated α-synuclein in Parkinson's disease
por: Yang, Bojie, et al.
Publicado: (2023)

Molecular Basis of Small-Molecule Binding to α-Synuclein
por: Robustelli, Paul, et al.
Publicado: (2022)

Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients
por: Bhumkar, Akshay, et al.
Publicado: (2021)

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
por: Schulz-Schaeffer, Walter J.
Publicado: (2010)

Acceleration of α-Synuclein Aggregation by Exosomes
por: Grey, Marie, et al.
Publicado: (2015)

New Roles of Glycosaminoglycans in α-Synuclein Aggregation in a Cellular Model of Parkinson Disease
por: Lehri-Boufala, Sonia, et al.
Publicado: (2015)

Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease
por: Basu, Sambuddha, et al.
Publicado: (2015)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
por: Recasens, Ariadna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qgho6ejupf0a21fvu86mp9h6td